Aktiesnakken — Juni 2010
-
jan er på nu
-
jeg er på!
-
We are a leading biotech company, we have brought a product on the market
-
Arzerra har blockbuster potentiale
-
(han er nervøs!)
-
high growth for the coming years
-
cancermarkedet fordobles indenfor 10 år!
-
yes nye info
-
Genmab er in the right spot
-
over 20 aktive studier med GSK
-
CD38 er også vigtigt 4 milliarder stort marked i 2013!
-
very broad pipeline - focused on cancer
-
experienced management team!
-
Ultimab teknologien førte alene sidste år til 4 bla
-
de rigtige værktøjer også for fremtiden
-
Arzerra blev bragt på markedet på 7 år
-
Det validerer vores evne til at få produkter på markedet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind